KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study.

Liangying Gan, Xinlu Gao, Jingchun Yao, Xinrong Xiong, Qingfeng Peng, Gang Long, Fei Xiong, Yiming Li, Qingping Chen, Yuan Qin, Qingdong Xu, Wenli Chen, Jinsheng Xu, Huixiao Zheng, Lin Yang, Xiangming Yi, Ning Cao, Yulan Shen, Bing Liu, Qiang Zhu, Pengfei Zhang, Henglan Wu, Junhua Shi, Yinhui Li, Yiwen Li, Baoxing Wang, Wenxiu Chang, Weimin Yu, Rui Wen, Cangsang Liu, Hongli Jiang, Rongshan Li, Jihong Ou, Xinxin Jiang, Aihua Zhang, Aicheng Yang, Yean Yu, Jiaqing Peng, Ke Xu, Xiuxian Wan, Yi Wang, Yongjun Shi, Pei Wang, Panna Liu, Xiaoran Feng, Hui Xu, Chun Yang, Xiaowen Li, Jianing Wang, Wenmei Zhang, Li Zuo

Ren Fail 47(1) 2597648

PMID41481110
PMCIDPMC12777750
DOI10.1080/0886022X.2025.2597648
发表日期2026-01-02
入排依据:未发现恶性肿瘤人群证据。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。
摘要

摘要

Recombinant human erythropoietin (rhEPO) fused with human immunoglobulin G (IgG) Fc fragment (rhEPO-Fc) is a novel erythropoiesis-stimulating agent designed to extend plasma half-life and enhance biological activity. However, data on the efficacy and safety of rhEPO-Fc in hemodialysis patients with chronic kidney disease (CKD)-related anemia remain limited. This phase 3 trial enrolled patients from 45 Chinese hospitals. Participants were randomized (2:1) to receive either rhEPO-Fc or rhEPO (Chinese hamster ovary cell-derived) for 28 weeks. The rhEPO-Fc responders were eligible for a 24-week extension period. The primary endpoint was the least square mean (LSM) change in hemoglobin (Hb) levels from baseline between weeks 21 and 28. Among 356 rhEPO-Fc and 178 rhEPO recipients, patients receiving rhEPO-Fc demonstrated non-inferiority Hb maintenance compared with rhEPO. The inter-group LSM differences in the full analysis set and per-protocol set were 3.96 g/L (95% CI: 3.02-4.89; p < 0.001) and 2.27 g/L (95% CI: 0.60-3.95; p = 0.008), respectively. Adverse drug reaction rates were comparable (rhEPO-Fc: 39.2% vs. rhEPO: 40.2%). Dose adjustments due to treatment-emergent adverse events were significantly lower with rhEPO-Fc (0.0% vs. 2.2%; p < 0.05). Deaths unrelated to the study drugs occurred in two rhEPO-Fc and four rhEPO patients. These findings indicated that rhEPO-Fc effectively maintained Hb levels in patients with CKD anemia undergoing hemodialysis, showing comparable efficacy to rhEPO with reduced dosing frequency and a similar safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Patient flow diagram.
非 KM Figure